ArticleTherapeutics and clinical risk management2007
The role of tramadol in current treatment strategies for musculoskeletal pain.
Article in Therapeutics and clinical risk management, 2007. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 20 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
20 citing papers in PubMed, 2 syntheses or guidelines pooled it, 45 citations in OpenAlex.
- Tramadol (with or without acetaminophen) efficacy and harm: Systematic review and meta-analysis.Canadian family physician Medecin de famille canadien · 2025Pooled it
- Safety and efficacy of "on-demand" tramadol in patients with premature ejaculation: an updated meta-analysis.International braz j urol : official journal of the Brazilian Society of UrologyPooled it
- Two prophylactic medication approaches in addition to a pain control regimen for early medical abortion < 63 days' gestation with mifepristone and misoprostol: study protocol for a randomized, controlled trial.Reproductive health · 2016Trial
- Reframing myofascial pain syndrome: pathological disorder or adaptive protective response?Therapeutic advances in musculoskeletal disease · 2026Review
- Tramadol for chronic pain in adults: protocol for a systematic review with meta-analysis and trial sequential analysis of randomised clinical trials.Systematic reviews · 2023Article
- Multimechanistic Single-Entity Combinations for Chronic Pain Control: A Narrative Review.Cureus · 2022Review
- Analgesic Medication in Fibromyalgia Patients: A Cross-Sectional Study.Pain research & management · 2022Article
- Article
- Pain management in hidradenitis suppurativa and a proposed treatment algorithm.Journal of the American Academy of Dermatology · 2021Review
- Safety Events Associated with Tramadol Use Among Older Adults with Osteoarthritis.Population health management · 2021Article
- North American clinical management guidelines for hidradenitis suppurativa: A publication from the United States and Canadian Hidradenitis Suppurativa Foundations: Part I: Diagnosis, evaluation, and the use of complementary and procedural management.Journal of the American Academy of Dermatology · 2019Review
- Tramadol: a valuable treatment for pain in Southeast Asian countries.Journal of pain research · 2018Article
- Durapain in symptomatic treatment of severe acute pain: a post-marketing, prospective, multicenter, observational study - PRIME study.Journal of pain research · 2017Article
- Predictive factors and clinical biomarkers for treatment in patients with chronic pain caused by osteoarthritis with a central sensitisation component.International journal of clinical practice · 2016Review
- [Conversion to tapentadol PR improves analgesia and quality of life in patients with severe and chronic pain despite using tramadol > 300 mg/d].Wiener klinische Wochenschrift · 2015Article
- Practice of Pain Management by Indian Healthcare Practitioners: Results of a Paper Based Questionnaire Survey.Pain research and treatment · 2015Article
- Review of extended-release formulations of Tramadol for the management of chronic non-cancer pain: focus on marketed formulations.Journal of pain research · 2014Review
- Efficacy and safety profile of combination of tramadol-diclofenac versus tramadol-paracetamol in patients with acute musculoskeletal conditions, postoperative pain, and acute flare of osteoarthritis and rheumatoid arthritis: a Phase III, 5-day open-label study.Journal of pain research · 2014Article
- [Opioid therapy in patients with back pain. Claims data analysis for patient group characterization, influence on opioid therapy and work disability].Schmerz (Berlin, Germany) · 2011Article
- Tramadol/paracetamol fixed-dose combination: a review of its use in the management of moderate to severe pain.Clinical drug investigation · 2010Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
1 author at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Non-selective and cyclooxygenase-2 (COX-2) selective non-steroidal anti-inflammatory drugs (NSAIDs) have been the mainstay of treatment for musculoskeletal pain of moderate intensity. However, in addition to gastrointestinal and renal toxicity, an increased cardiovascular risk may be a class effect for all NSAIDs. Despite these safety risks and the acknowledged ceiling effect of NSAIDs, many doctors still use them to treat moderate, mostly musculoskeletal pain. Recent guidelines for treating osteoarthritis and low back pain, issued by numerous professional medical societies, recommend NSAIDs and COX-2 inhibitors only in strictly defined circumstances, at the lowest effective dose and for the shortest possible period of time. These recent guidelines bring more focus to the usage of paracetamol and opioids. But opioids still remain under-utilized, although they are effective with minimal organ toxicity. In this setting, the atypical, centrally acting analgesic tramadol offers important benefits. Its multi-modal effect results from a dual mode of action, ie, opioid and monoaminergic mechanisms, with efficacy in both nociceptive and neuropathic pain. Moreover, fewer instances of side effects such as constipation, respiratory depression, and sedation occur than with traditional opioids, and tramadol has been prescribed for 30 years for a broad range of indications. Tramadol is now regarded as the first-line analgesic for many musculoskeletal indications. In conclusion, it is recommended to better implement the more recent guidelines focusing on pain management and consider the role of tramadol in musculoskeletal pain treatment strategies.
Indexed as
Identifiers
18472996PMC2376082W1929659326What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.